Sharmila Dorbala, MD, MPH, FASNC, Chair*; Yukio Ando, MD, PhD†; Sabahat Bokhari,
MD‡; Angela Dispenzieri, MD § ; Rodney H. Falk, MD*; Victor A. Ferrari, MD∥; Marianna …

Systemic forms of amyloidosis affecting the heart are mostly light-chain (AL) and
transthyretin (ATTR) amyloidoses. The latter is caused by deposition of misfolded …

Nearly half of all patients with heart failure (HF) have a normal left ventricular (LV) ejection
fraction (EF) and the condition is termed heart failure with preserved ejection fraction …

[CQ1] What is the role of 99 mTc-PYP scintigraphy (bone scintigraphy) in clinical practice for
CA?∙∙∙∙∙∙ 1655 [CQ2] The role of endomyocardial biopsy. Which site is appropriate for biopsy …

Cardiac amyloidosis (CA) is an infiltrative and restrictive cardiomyopathy that leads to heart
failure, reduced quality of life, and death. The disease has two main subtypes, transthyretin …

Aims The study aims to systematically assess the diagnostic performance of cardiac
magnetic resonance (CMR) and nuclear scintigraphy (index tests) for the diagnosis and …

Amyloidosis is a collection of systemic diseases characterised by misfolding of previously
soluble precursor proteins that become infiltrative depositions, thereby disrupting normal …

Amyloid light chain (AL) amyloidosis is a rare, debilitating, often fatal disease. Symptoms of
cardiomyopathy are common presenting features, and patients often are referred to …

Heart failure with preserved ejection fraction (HFpEF) is an increasingly diagnosed condition
whose failure to respond to new drugs effective in heart failure with reduced ejection fraction …

Abstract Purpose of Review Heart failure with preserved ejection fraction (HFpEF) is a
relatively new disease entity used in medical terminology; however, both the number of …